The Significance of Circulating Microvesicles in Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-30

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mild to moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased survival. A small proportion of COPD patients may present with severe pulmonary hypertension, defined by a mean pulmonary artery pressure more than 35 mmHg (or more than 20 mmHg with a low cardiac index \< 2 l/min/m2) with pulmonary vascular resistance more than 3 Wood units, measured by right heart catheterization (RHC). In these patients, pulmonary microvessels remodeling is the main cause of increase in pulmonary arterial pressure and is thought to result from the combined effects of hypoxia, inflammation, and loss of capillaries but the mechanisms are complex.

For these patients, no drugs have been approved for treatment and lung transplantation must be considered for the more severe patients who are eligible. A better characterization of these patients is needed.

We hypothesize that microvesicles generation and endothelial damage could be related to the severity of pulmonary hypertension due to COPD, assessed by pulmonary hemodynamic parameters. Circulating biomarkers of vascular damage and cell activation will be measured in blood samples from 80 COPD patients who have hemodynamic assessment by RHC. To go further, the origin of the particles will be characterized.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy

NCT06613321

Copd Hypertension, Pulmonary Hyperdistention

COMPLETED

Cardiovascular Risk and Chronic Obstructive Pulmonary Disease

NCT03014609

Chronic Obstructive Pulmonary Disease

RECRUITING

Prevalence of Pulmonary Hypertension in COPD Patients

NCT00614900

COPD Pulmonary Hypertension

COMPLETED

Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!

NCT01314807

Chronic Obstructive Pulmonary Disease

UNKNOWN

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

NCT05704881

Pulmonary Disease, Chronic Obstructive Exacerbation Copd

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease Circulating Microvesicles Circulating Markers of Endothelium Damage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Catheterization

Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18
* COPD: obstructive ventilatory insufficient on spirometry and history of smoking
* patients who will perform right heart catheterization
* Signature of written informed consent

Exclusion Criteria

* LVEF \< 45% (echocardiography)
* Post-capillary pulmonary hypertension (pulmonary capillary wedge pressure \> 15 mmHg)
* Chronic Thromboembolic hypertension
* Pulmonary embolism \< 6 months
* Acute coronary syndrome \< 3 months
* Significant cardiac valvulopathy (echocardiography)
* Portal hypertension
* Connective tissue disease
* chronic renal insufficient (clearance \< 40 ml/min)
* Glycated hemoglobin \> 7% (if diabetes)
* Non controlled arterial hypertension
* Positive beta-HCG
* Respiratory exacerbation during the inclusive period
* Patients under guardianship or curatorship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No